Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,809 questions · 1,956 findings · 194 reviews

No studies found 422 · 21.6%GRADE not reported 427 · 21.8%Very low 353 · 18%Low 397 · 20.3%Moderate 293 · 15%High 64 · 3.3%

Comparison 2: 7 days oral amoxicillin + injectable gentamicin vs 7 days injectable benzylpenicillin + injectable gentamicin

Treatment failure · neonates with possible serious bacterial infection

Comparison 2: 7 days oral amoxicillin + injectable gentamicin showed no clear difference in treatment failure compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).

1 finding from 1 review

Comparison 2: 7 days oral amoxicillin + injectable gentamicin vs 7 days injectable benzylpenicillin + injectable gentamicin

Adverse events · neonates with possible serious bacterial infection

Comparison 2: 7 days oral amoxicillin + injectable gentamicin showed no clear difference in adverse events compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).

1 finding from 1 review

Commercial mouthcare system (Biotene Oral Balance / Xerostom) vs Usual care or CMC-based control

Unstimulated whole saliva (UWS) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…

Commercial mouthcare system (Biotene Oral Balance / Xerostom) showed no clear difference in salivary flow (unstimulated whole saliva) compared with usual care or CMC-based control; GRADE not reported.

1 finding from 1 review

Commercial mouthcare system (Biotene Oral Balance / Xerostom) vs Usual care or CMC-based control

Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…

Commercial mouthcare system (Biotene Oral Balance / Xerostom) led to higher xerostomia (VAS mouth dryness) compared with usual care or CMC-based control; GRADE not reported.

1 finding from 1 review

Slow-release fluoride device (fluoride glass beads) vs Fluoride mouthrinse

Number of participants with more severe DLs (severity of DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

The review found no eligible studies for this question.

1 finding from 1 review

Slow-release fluoride device (fluoride glass beads) vs Fluoride mouthrinse

Adverse effects · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)
1 finding from 1 review

Slow-release fluoride device (fluoride glass beads) vs Fluoride mouthrinse

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

It is very uncertain whether intraoral fluoride-releasing glass bead device attached to the brace changes number of participants with new demineralised lesions (DLs) compared with 250 ppm F (daily) fluoride mouthrinse (very low certainty).

1 finding from 1 review

Reassurance / behavioral management (control of contributory factors)

Outcome not reported · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

MACE · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in MACE compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Death · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in death compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in all major occlusive vascular events compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in intracerebral haemorrhage (ICH) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Functional outcomes · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in fnctional status (mRS 0‐2) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4 days) vs Tinidazole (1 g per day for 3 days)

Total effective rate at 4 days · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4… showed no clear difference in total effective rate at 4 days compared with tinidazole (1 g per day for 3 days); GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.

1 finding from 1 review

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Days to resolution of pain / epithelialization; number of aphthae per month · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • Femiano 2003 (high risk of bias) reports days to resolution of pain and days to epithelialization of aphthae at 1 month, and number of aphthae per month after the first and second months; data presented as…
    1 study · 20 participants
    GRADE not reported